Big pharma’s in-house manufacturing impacted by COVID-19 outbreak in China
According to an outlet, the in-house manufacturing of biopharma products has been threatened by the COVID-19 outbreak, especially in China.
List view / Grid view
According to an outlet, the in-house manufacturing of biopharma products has been threatened by the COVID-19 outbreak, especially in China.
A new observational study has identified no benefit from prescribing statins to healthy pensioners aged over 75 to prevent heart disease...